TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02123927

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-438
Description: TAK-438 tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-438
Description: TAK-438 tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-438
Description: TAK-438 tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-438
Description: TAK-438 tablets
Study: NCT04648540

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fentanyl 1 mic/kg/hr
Description: In Group II (OA) patients will receive a continuous infusion of Fentanyl (1 mic/kg/h) Morphine 0.1 mg/kg PRN will be administered every 8 hours for postoperative analgesia
Study: NCT03479697

Intervention type: DEVICE
Group type: OTHER
Intervention: HIRREM
Description: Technology

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: HIRREM
Description: Technology

Intervention type: OTHER
Group type: OTHER
Intervention: Continued Current Care
Description: Continue their current clinical care.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Continued Current Care
Description: Continue their current clinical care.
Study: NCT02123927

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-438
Description: TAK-438 tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-438
Description: TAK-438 tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-438
Description: TAK-438 tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-438
Description: TAK-438 tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-438
Description: TAK-438 tablets
Study: NCT04109274

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise
Description: Exercise component: Aerobic exercise, using recumbent bikes, delivered within the cancer institution. Participants will take part in up to 30-minutes of moderate intensity (50-70% HRmax or 4-6/10 on Rate of Perceived Exertion scale)6 exercise for eight sessions during chemotherapy. An exercise specialist with experience in cancer rehabilitation will supervise the exercise component.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Self-Management
Description: Eight SM modules will be delivered to participants. They will be viewed on an iPad prior to or after the exercise component. The goal of these modules is to aid participants in developing physical activity goals and action plans to continue with between sessions, with an overarching goal of helping them reach exercise guidelines for cancer survivors and the Canadian Physical Activity Guidelines

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Self-Management
Description: Eight SM modules will be delivered to participants. They will be viewed on an iPad prior to or after the exercise component. The goal of these modules is to aid participants in developing physical activity goals and action plans to continue with between sessions, with an overarching goal of helping them reach exercise guidelines for cancer survivors and the Canadian Physical Activity Guidelines

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Booster Sessions
Description: Four booster sessions will be provided to participants in this group. These will occur at 2, 4, 6, and 8 months post intervention completion. An assessor trained in behavioural counselling will provide booster sessions by phone and will discuss the individuals physical and emotional condition, current exercise level, accomplishment of previously set goals and action plans, and perceived barriers to participation in exercise. The assessor will use facilitation strategies to aid participants in devising strategies to overcome barriers and set realistic goals and action plans.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Booster Sessions
Description: Four booster sessions will be provided to participants in this group. These will occur at 2, 4, 6, and 8 months post intervention completion. An assessor trained in behavioural counselling will provide booster sessions by phone and will discuss the individuals physical and emotional condition, current exercise level, accomplishment of previously set goals and action plans, and perceived barriers to participation in exercise. The assessor will use facilitation strategies to aid participants in devising strategies to overcome barriers and set realistic goals and action plans.
Study: NCT06253364

Intervention type: DRUG
Intervention: PD-1 monoclonal antibody and lenvatinib
Description: Adjuvant PD-1 group: Patient receives first adjuvant PD-1 monoclonal antibody 2-4 weeks postoperatively, 200mg IV over 21 days for 9 cycles.~Adjuvant PD-1 plus Lenvatinib group: Patient receives first adjuvant PD-1 monoclonal antibody 2-4 weeks postoperatively, 200 mg IV 21 days for 9 cycles; lenvatinib is initiated orally 2-4 weeks postoperatively for 6 months.

Intervention type: DRUG
Intervention: PD-1 monoclonal antibody and lenvatinib
Description: Adjuvant PD-1 group: Patient receives first adjuvant PD-1 monoclonal antibody 2-4 weeks postoperatively, 200mg IV over 21 days for 9 cycles.~Adjuvant PD-1 plus Lenvatinib group: Patient receives first adjuvant PD-1 monoclonal antibody 2-4 weeks postoperatively, 200 mg IV 21 days for 9 cycles; lenvatinib is initiated orally 2-4 weeks postoperatively for 6 months.
Study: NCT02123927

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-438
Description: TAK-438 tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-438
Description: TAK-438 tablets

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: TAK-438 placebo-matching tablets

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: TAK-438 placebo-matching tablets
Study: NCT02857881

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: De-epithelization and therapeutic photokeratectomy
Study: NCT02020603

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: epinephrine injection plus soft coagulation using hemostatic forceps

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: epinephrine injection plus argon plasma coagulation
Study: NCT03922477

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: Atezolizumab will be administered to participants by IV infusion at a fixed dose starting on Day 22 of Cycle 1. In subsequent cycles (Cycles 2 and beyond), IV atezolizumab will be given every 2 weeks (Q2W) on Days 8 and 22 of each 28-day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hu5F9-G4
Description: Two priming doses of 1 mg/kg of Hu5F9-G4 will be administered to participants by continuous IV infusion on Days 1 and 4 of Cycle 1, followed by loading doses of 15 mg/kg IV on Day 8 and 30 mg/kg IV on Day 11. Starting on Day 15 of Cycle 1, Hu5F9-G4 maintenance will be given by IV infusion at a dose of 30 mg/kg once a week (QW) of each 28-day cycle. Dosing for de-escalation, if needed: Hu5F9-G4 will be given as two priming doses of 1 mg/kg IV on Days 1 and 4, followed by loading doses of 10 mg/kg IV on Day 8 and 15 mg/kg on Day 11. Starting on Day 15, maintenance treatment with Hu5F9-G4 will be given by IV infusion at a dose of 15 mg/kg once a week (QW).
Study: NCT03058705

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hexaminolevulinate HCL
Description: Intravesical instillation of 100 mg hexaminolevulinate HCL will be performed via foley catheter at the initiation of the procedure. Although NIRF is more sensitive than bluelight cystoscopy, the current FDA approved dose will be used. Hexaminolevulinate has a favorable safety profile at this dose.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Near Infrared Fluorescence (NIRF)
Description: NIRF is a highly sensitive multi-spectral imaging modality that speeds the detection of bladder cancer fluorescence after infusion of hexaminolevinulate.
Study: NCT01684943

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Multiplex pharmacokinetic profiling
Study: NCT00553930

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pegylated interferon alfa-2a and Ribavirin
Description: All patients will be treated with the combination of pegIFN-α 2a (135 μg per week)plus oral Ribavirin at a dose of 800 mg per day. The treatment will be continued up to 20 weeks after reaching an undetectable plasma RNA-HCV. Treatment will be discontinued for patients who did not achieve a reduction of al least 2 log10 IU/ml in plasma HCV RNA levels with respect to baseline at week 12 and will be considered as viral failures.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pegylated interferon alfa 2a and Ribavirin
Description: Pegylated interferon alfa 2a (135 ug/week)and Ribavirin (800 mg/day). Duration: 20 weeks after reaching an undetectable plasma RNA_HCV. Treatment will be discontinued for patients who did not achieve a decrease of \>= 2 log10 IU/ml in plasma HCV RNA levels with respect to baseline at week 12 of treatment or earlier and will be considered as viral failures.
Study: NCT01684943

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Continuous insulin monitoring
Study: NCT00596817

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: capsules, daily, orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vortioxetine (Lu AA21004)
Description: encapsulated tablets, daily, orally
Study: NCT02924168

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Active Radial Shockwave
Description: Four weekly sessions of active radial shockwave treatment.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham Radial Shockwave
Description: Four weekly sessions of sham radial shockwave treatment.
Study: NCT01989325

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carfilzomib, proteasome inhibitor; intravenous
Description: multiple dose, single schedule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carfilzomib, proteasome inhibitor; intravenous
Description: multiple dose, single schedule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Filanesib, KSP(Eg5) inhibitor; intravenous
Description: multiple dose, single schedule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone, steroid; oral or intravenous
Description: as indicated, per the carfilzomib prescribing information

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone, steroid; oral or intravenous
Description: as indicated, per the carfilzomib prescribing information

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Filgrastim, granulocyte-colony stimulating factor (G-CSF); subcutaneous
Description: standard of care
Study: NCT03683927

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Bacillus clausii
Description: The probiotic (Bacillus clausii) will be administered 4 times a week to the infant

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Sterile water
Description: The placebo group will receive sterile water 4 times a week
Study: NCT02625532

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Follicular phase
Description: Controlled ovarian stimulation starts on day 2-3 of the menstrual cycle with recombinant recombinant FSH + LH, adding cetrorelix when the follicles reach 14 mm size and ovarian maturation with triptorelin acetate

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Luteal phase
Description: Controlled ovarian stimulation is started between 3rd and 5th day after the first LH positive urine test, adding cetrorelix when follicles reached 14 mm size and ovarian maturation with triptorelin acetate
Study: NCT01328977

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: education
Description: teaching

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: education
Description: teaching

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: education
Description: teaching
Study: NCT00842920

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Simvastatin 60 mg
Description: 60 mg once daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: one tablet once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Simvastatin 20 mg
Description: 20 mg once daily
Study: NCT01022320

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Lateral Pharyngoplasty
Description: surgery lateral pharyngoplasty: consists on the section and rotation of the superior constrictor pharyngeal muscle associated with the ressection of the palatopharyngeus preserving the palatoglossus and mucosa of posterior and anterior tonsilar pillar , bilaterally.
Study: NCT02385838

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: 5-CNL
Description: The 5-CNL front-of-pack nutrition label is introduced on foodstuffs in a controlled shopping environment

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: MTL
Description: The MTL front-of-pack nutrition label is introduced on foodstuffs in a controlled shopping environment

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: GDA
Description: The GDA front-of-pack nutrition label is introduced on foodstuffs in a controlled shopping environment

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Tick
Description: The Tick front-of-pack nutrition label is introduced on foodstuffs in a controlled shopping environment
Study: NCT02451774

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pentoxifylline Plus Chemotherapy
Description: Pentoxifylline 10 to 20 milligrams per kilogram, daily, for up to 32 days Chemotherapy: Prednisone 40 milligrams per square meter per day, orally, day 5-32. Vincristine 1.5 milligrams per square meter per week, intravenously, day 5, 12, 19, 26. Daunorubicin 25 milligrams per square meter per week, intravenously, days 5; 12. L-asparaginase 10,000 units for square meter, intramuscular, days 6, 8, 10, 12, 14, 16, 19, 21, 23. Cyclophosphamide 1000 milligrams per square meter per dose intravenously, day 26. Cytarabine 75 milligrams per square meter per dose intravenously, days 27-30, 34-37. 6-Mercaptopurine 60 milligrams per square meter per dose, orally, days 26-39, Mix: Methotrexate 8-12 milligrams, Hydrocortisone 16-24 milligrams and Cytarabine 24-36 milligrams, intrathecal, day 19.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Plus Chemotherapy
Description: Placebo daily, for up to 32 days Chemotherapy: Prednisone 40 milligrams per square meter per day, orally, day 5-32. Vincristine 1.5 milligrams per square meter per week, intravenously, day 5, 12, 19, 26. Daunorubicin 25 milligrams per square meter per week, intravenously, days 5; 12. L-asparaginase 10,000 units for square meter, intramuscular, days 6, 8, 10, 12, 14, 16, 19, 21, 23. Cyclophosphamide 1000 milligrams per square meter per dose intravenously, day 26. Cytarabine 75 milligrams per square meter per dose intravenously, days 27-30, 34-37. 6-Mercaptopurine 60 milligrams per square meter per dose, orally, days 26-39, Mix: Methotrexate 8-12 milligrams, Hydrocortisone 16-24 milligrams and Cytarabine 24-36 milligrams, intrathecal, day 19.
Study: NCT03079141

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Eplerenone
Description: Patients will receive 25 milligrams oral eplerenone once daily for a week, and - when no abnormalities during blood testing for potassium and renal clearance can be detected both before treatment and during the first week of treatment - will receive 50 milligrams oral eplerenone for another 11 weeks thereafter.~When patients are randomized to the eplerenone arm of this study, they will receive this treatment as a first cCSC treatment. Moreover, eplerenone treatment can be initiated in patients in whom SRF is still present on OCT at the Evaluation Visit at 3 months after PDT treatment.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Photodynamic therapy
Description: In the PDT treatment arm, all patients will receive an intravenous drip through which half-dose (3 mg/m2) verteporfin (Visudyne®) is administered, with an infusion time of 10 minutes. At exactly 15 minutes after the start of the infusion, PDT laser treatment is performed with standard 50 J/cm2 fluency, a wavelength of 689 nm, and a treatment duration of 83 seconds.~When patients are randomized to the PDT arm of this study, they will receive this treatment as a first cCSC treatment. Moreover, PDT can be performed in patients in whom SRF is still present on OCT at the Evaluation Visit at 3 months after the start of eplerenone treatment.
Study: NCT04141501

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Psilocybin
Description: single dose of psilocybin (25mg). orally in form of a capsule

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo oral capsule
Description: single dose of mannitol (100%)
Study: NCT02914704

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MRI-HIFU
Description: Treatment of uterine fibroids with MRI-HIFU
Study: NCT00667823

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Macitentan
Description: Tablet, oral administration, 10 mg dose once daily
Study: NCT01492374

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-241027
Description: Intravenous (IV), 0.003 mg/kg, Once Weekly, 9 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-241027
Description: Intravenous (IV), 0.01 mg/kg, Once Weekly, 9 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-241027
Description: Intravenous (IV), 0.03 mg/kg, Once Weekly, 9 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo matching BMS-241027
Description: Intravenous (IV), 0.0 mg/kg, Once Weekly, 9 weeks
Study: NCT03106363

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: delta 9 tetrahydrocannabinol
Description: A single cannabis cigarette (potency 12.5% delta 9 tetrahydrocannabinol) will be given to participants to smoke over a 10 minute period, ad libitum. If the cannabis cigarette is not smoked in its entirety, the remainder will be weighed to estimate dose.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: delta 9 tetrahydrocannabinol
Description: A single cannabis cigarette (potency 12.5% delta 9 tetrahydrocannabinol) will be given to participants to smoke over a 10 minute period, ad libitum. If the cannabis cigarette is not smoked in its entirety, the remainder will be weighed to estimate dose.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: placebo delta 9 tetrahydrocannabinol
Description: A single placebo cannabis cigarette (\<0.03% delta 9 tetrahydrocannabinol) will be given to participants to smoke over a 10 minute period, ad libitum. If the placebo cannabis cigarette is not smoked in its entirety, the remainder will be weighed to estimate dose (as this is a double-blind study).

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo delta 9 tetrahydrocannabinol
Description: A single placebo cannabis cigarette (\<0.03% delta 9 tetrahydrocannabinol) will be given to participants to smoke over a 10 minute period, ad libitum. If the placebo cannabis cigarette is not smoked in its entirety, the remainder will be weighed to estimate dose (as this is a double-blind study).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Alcohol
Description: A single oral administration of an alcoholic beverage mixed in a 1:3 ratio of alcohol to tonic water to obtain a target blood alcohol content of 0.08mg%.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Alcohol
Description: A single oral administration of an alcoholic beverage mixed in a 1:3 ratio of alcohol to tonic water to obtain a target blood alcohol content of 0.08mg%.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo alcohol
Description: A single oral administration of a beverage containing tonic water of the same volume as the alcoholic beverage.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo alcohol
Description: A single oral administration of a beverage containing tonic water of the same volume as the alcoholic beverage.
Study: NCT04398212

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: mfERG (multifocal-retinogram)
Description: mfERG will be performed for the students to document the effect of CVS on retina

Intervention type: DIAGNOSTIC_TEST
Group type: PLACEBO_COMPARATOR
Intervention: mfERG (multifocal-retinogram)
Description: mfERG will be performed for the students to document the effect of CVS on retina
Study: NCT03994068

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: VIVO non invasive mapping
Description: non invasive pre-procedural localization of PVC / VT origin
Study: NCT02080780

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clarithromycin XL
Description: Clarithromycin XL administered once daily on Days 4 through 9 as 2 x 500 mg tablets, 1000 mg per day, for a total of 6000 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 2% Diltiazem
Description: 2% Diltiazem Hydrochloride Cream applied on Day 1 \& Day 8 to the perianal area (\~2.5 cm \[1 inch\]; \~8.5 mg)
Study: NCT03153579

Intervention type: DRUG
Group type: OTHER
Intervention: LSD
Description: Lysergic Acid Diethylamide~200ug per os, single dose

Intervention type: DRUG
Group type: OTHER
Intervention: Placebo
Description: Capsules containing mannitol looking identical to LSD
Study: NCT04348383

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo 250 cc every 6 hours for 7 or15 days
Study: NCT02266589

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydrocortisone
Description: Hydrocortisone hemisuccinate (Roussel-Uclaf, Romainville, France), 50 mg intravenously every 6 hrs
Study: NCT01637779

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Fact sheet
Description: fact sheet about pain management during immunization

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Fact sheet
Description: fact sheet about pain management during immunization

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Fact sheet
Description: fact sheet about pain management during immunization

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Fact sheet
Description: fact sheet about pain management during immunization
Study: NCT04310553

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Irreversible electroporation
Description: Patients with locally advanced pancreatic cancer diagnosed by cell / histopathology will receive nano knife treatment if the target lesion is not suitable for surgical resection or the target lesion is suitable for surgical resection but patients give up surgery and choose nano knife combined with chemotherapy. Patients who have not previously received first-line chemotherapy will receive systemic chemotherapy for 4-6 cycles of treatment. Imaging evaluation will be performed every 6-8 weeks (± 7 days) during chemotherapy.
Study: NCT02840357

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Purple Wheat Convenience Bars
Description: Whole grain convenience bars manufactured with purple wheat

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Control Wheat Convenience Bars
Description: Whole grain convenience bars manufactured with ordinary wheat
Study: NCT04604080

Intervention type: OTHER
Intervention: service of questionnaire
Description: Respondents will be given a survey form only and after filling this will be collected back